West African–South American Pandemic Vibrio Cholerae Encodes Multiple Distinct Phage Defence Systems

West African–South American pandemic Vibrio cholerae encodes multiple distinct phage defence systems

Our understanding of the factors underlying the evolutionary success of different lineages of pandemic Vibrio cholerae remains incomplete. The West African–South American (WASA) lineage of V. cholerae, responsible for the 1991–2001 Latin American cholera epidemic, is defined by two unique genetic signatures. Here we show that these signatures encode multiple distinct anti-phage defence systems. Firstly, the WASA-1 prophage encodes an abortive-in…

India has developed a vaccine against a deadly disease like cholera. This vaccine has raised new hopes in the world. Its trial on 18 thousand people has been successful. Let us know the seriousness of this disease, the specialty of the vaccine and the prevention tips of experts.

New Guardians at the Gate: Inflammation and Cell Death - BioPatrika

Research Summary: Vibrio cholerae cytolysin (VCC), a pore-forming toxin of cholera pathogen, engages novel innate receptor assembly (TLR1/4) to trigger inflammation and death, critical for bacterial pathogenesis.  Novel TLR Signalling Orchestrates Inflammation and Cell Death Author interview: Ms. Shraddha Gandhi is an immunologist with a background in Biotechnology. She earned her Bachelor’s degree in Biotechnology from […] The post New Guardian…

Bharat Biotech’s Oral Cholera Vaccine Clears Phase III Trials...

Last Updated on May 22, 2025 by Team THIP Bharat Biotech has announced the successful completion of Phase III clinical trials for its oral cholera vaccine, Hillchol. The trials demonstrated the vaccine’s efficacy against both Ogawa and Inaba serotypes of cholera, marking a significant milestone in cholera prevention and public health. The double-blind, randomized study involved […] The post Bharat Biotech’s Oral Cholera Vaccine Clears Phase III …

Hillchol®: Bharat Biotech’s Oral Cholera Vaccine Demonstrates Success in Phase III Clinical Studies

Bharat Biotech’s Oral Cholera Vaccine Hillchol® has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV.The above study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a double-blind, randomized phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single …

Hillchol: Bharat Biotech’s oral cholera vaccine demonstrates success in phase III clinical studies - Express Pharma

Bharat Biotech’s Oral Cholera Vaccine Hillchol has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV. The above study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority and lot-to-lot consistency of singl…